- Home
- VRCA vs IXHL Comparison
VRCA vs IXHL Comparison
Compare VRCA & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | IXHL |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 97.6M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VRCA | IXHL |
|---|---|---|
| Price | $6.11 | $3.20 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 125.6K | ★ 4.1M |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $12,000.00 |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $0.11 |
| 52 Week High | $9.82 | $6.39 |
Technical Indicators
Market Signals| Indicator | VRCA | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 56.41 |
| Support Level | $5.22 | $0.31 |
| Resistance Level | $6.44 | $5.17 |
| Average True Range (ATR) | 0.46 | 0.51 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 70.51 | 49.82 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.